Table 2.

Consensus statements of EGb from the Asian Clinical Expert Group on Neurocognitive Disorders.

No	Consensus statement	Concrete content
1	Efficacy of EGb 761® in AD, VaD, and BPSD	Best practice for the pharmacological treatment as follows:
		AD: AChEI, memantine, EGb
		VaD: AChEI, memantine, EGb, antiplatelet therapy
		BPSD: ChEI, nonpharmacological treatment, antipsychotics (off-label), memantine, SSRIs, sedatives, and EGb
2	Management of MCI	EGb may be considered for use in patients with MCI
3	How to use EGb	EGb can be used as a single agent, and allow sufficient time to take effect
4	The dosage	EGb at daily dose of 240 mg
5	Lack of efficacy or intolerance of standard drugs may warrant use of EGb	EGb was recommended to treat AD, VaD, and mixed dementia, when the patients unable to tolerate the side effects of standard treatments
6	Adjunctive therapies	EGb was one of the key management options adjunctive to standard pharmacological therapy for AD, VaD, and BPSD
7	Management of comorbidities	EGb played an important role in the management of co-morbidities, such as hypertension, in patients with AD, VaD, and BPSD
8	Does not appear to prevent dementia	EGb was not recommended for prevention of dementia
9	Well tolerated	EGb had a good tolerability profile in the treatment of MCI, AD, VaD, and BPSD
10	No overall increased bleeding risk	EGb appeared to be no overall added risk of bleeding
11	No significant interaction with anticoagulants or antiplatelet agents	EGb had been demonstrated no significant interaction with anticoagulants and antiplatelet agents

AD, Alzheimer’s disease; VaD, vascular dementia; BPSD, behavioral and psychological symptoms of dementia; MCI, mild cognitive impairment; AChEI, acetylcholinesterase inhibitors; SSRIs, Selective Serotonin Reuptake Inhibitors.